Risk of Failure or Delays in New Drug Development
First written in FY2016. 7 of 8 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.
28 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Research and development of pharmaceuticals and other products requires substantial funding and a long period of time, but development may be interrupted or delayed if, for example, the efficacy initially expected cannot be demonstrated or unexpected adverse reactions emerge.」
The risks of failure to achieve projected earnings due to interruption or delays in research and development, additional trials and the loss of future sales opportunities are reaffirmed. - FY2025RestatedAnnual report
「Research and development of pharmaceuticals and other products requires substantial funding and a long period of time, but development may be interrupted or delayed if, for example, the efficacy initially expected cannot be demonstrated or unexpected adverse reactions emerge.」
The risks of failure to achieve projected earnings due to interruption or delays in research and development, additional trials and the loss of future sales opportunities are reaffirmed. - FY2022RestatedAnnual report
「Research and development of pharmaceuticals and other products requires substantial funding and a long period of time, but development may be interrupted or delayed if, for example, the efficacy initially expected cannot be demonstrated or unexpected adverse reactions emerge.」
The risks of failure to achieve projected earnings due to interruption or delays in research and development, additional trials and the loss of future sales opportunities are reaffirmed. - FY2021RestatedAnnual report
「Development may be interrupted or delayed if, for example, the efficacy initially expected cannot be demonstrated or unexpected adverse reactions emerge. This may result in repeated development work, additional trials and the loss of future sales opportunities, potentially causing earnings to fall below initial expectations.」
The risks of failure to achieve projected earnings due to interruption or delays in new drug development, additional trials and the loss of future sales opportunities are reaffirmed. - FY2020RestatedAnnual report
「Development may be interrupted or delayed if, for example, the efficacy initially expected cannot be demonstrated or unexpected adverse reactions emerge.」
The risk of failure to achieve projected earnings due to interruption or delays in new drug development is reiterated. - FY2019RestatedAnnual report
「Development may be abandoned or delayed if, for example, the efficacy initially expected cannot be demonstrated or unexpected adverse reactions emerge, potentially resulting in earnings below the initial projections.」
The risk of failure to achieve projected earnings due to failure or delays in new drug development is reiterated. - FY2018RestatedAnnual report
「Development may be abandoned or delayed if, for example, the efficacy initially expected cannot be demonstrated or unexpected adverse reactions emerge, potentially resulting in earnings below the initial projections.」
The risk of failure to achieve projected earnings due to failure or delays in new drug development is reiterated. - FY2016First statedAnnual report
「Development may be abandoned or delayed if, for example, the efficacy initially expected cannot be demonstrated or unexpected adverse reactions emerge, potentially resulting in earnings below the initial projections.」
This was described as uncertainty regarding the monetization of research and development investment.